Childhood cancer research gets million dollar boost
Published 16-DEC-2019 12:01 P.M.
3 minute read
Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.
In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.
The below articles were written under our previous business model. We have kept these articles online here for your reference.
Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.
Click Here to View Latest Articles
Australian Lions Childhood Cancer Research Foundation has announced it will provide $1.05 million of funding to the Telethon Kids Institute.
The funding will support the Telethon Kids Cancer Centre’s vital research aimed at improving survival rates, longevity and quality of life for children with cancer.
The Telethon Kids Institute is one of Australia’s largest independent health and medical research institutes, committed to discovering new and effective ways to enhance children’s health and wellbeing.
“At Australian Lions Childhood Cancer Research Foundation we believe every child deserves a chance at a healthy life,” Australian Lions Childhood Cancer Research Foundation Chairperson John Thorpe said. “We are very proud to be providing $1.05 million worth of funding to Telethon Kids.”
Chair of the Telethon Kids Institute, the Hon. Julie Bishop, said they are excited to be partnering with such a well-respected, community-oriented organisation like Lions Australia.
“We are so grateful for Australian Lions Childhood Cancer Research Foundation’s support,” Ms Bishop said. “This $1.05 million in funding will enable the Telethon Kids Cancer Centre to continue its leading research into childhood cancer – particularly in the area of cancer immunotherapy, which focuses on supercharging the body’s natural defences to destroy cancer cells.”
Headquartered in Perth at the Perth Children’s Hospital, the Telethon Kids Institute has an international reputation for the work it has undertaken over the past 30 years to prevent, cure or reduce harm from chronic, infectious and other severe diseases, neuro-developmental disorders, and mental health challenges that affect children.
Mr Thorpe described cancer immunotherapy as one of the most exciting and promising cancer treatments being developed, particularly for childhood cancer.
“It is our hope that this work will benefit kids all over Australia and beyond,” he said. “More than 800 children aged 0-14 years are diagnosed with cancer in Australia each year. Many of these cancers are aggressive and hard to treat and we are losing too many young lives.”
“Although survival rates have improved greatly for some, most cancers take a toll on young people’s lives and often side effects of treatment can be serious and lifelong.”
“Telethon Kids Cancer Centre’s research into cancer immunotherapy is focused on finding ways to help these children’s immune systems fight cancer cells. This will be revolutionary in the treatment of childhood cancer.”
Professor Terrance Johns, Head of the Telethon Kids Cancer Centre, said that as one of Australia’s only comprehensive, paediatric cancer immunotherapy centres, the Telethon Kids Cancer Centre was making its mark on medical research.
“The Centre is on a mission to prevent paediatric disease and improve the wellbeing of children with cancer. We bring together leading researchers and oncologists focused on developing therapies that destroy cancer cells, while minimising the side effects to children’s short and long-term health,” Professor Johns said.
The $1.05 million of funding to Telethon Kids Institute builds on the Australian Lions Childhood Cancer Research Foundation’s long history in supporting leading and innovative research into childhood cancer.
General Information Only
S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.
Conflicts of Interest Notice
S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.
Publication Notice and Disclaimer
The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.
Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.
This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.